Piper Sandler Rates AbbVie (ABBV) buy, $298 Price Target

Piper Sandler maintains its buy rating on AbbVie with a $298 price target, a 23% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 1:02 PM EDT · Updated Jun 26, 2026, 10:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Piper Sandler rated AbbVie Inc. ($ABBV) "buy" with a $298 price target on June 23, 2026.

Since the rating, $ABBV is up 7.2% after 1 week, up 10.2% after 1 month and up 23.2% to date (from the $231.68 close on Jun 23, 2026).

ABBV AbbVie Inc.

$285.42 +28.19% year to date

Daily close · Oct 16, 2026

Key Points

Piper Sandler reiterated its buy rating on AbbVie Inc. (ABBV) with a target price of $298 on June 23, 2026.
Piper Sandler's $298 price target implies 23% upside from AbbVie Inc.'s ($ABBV) current $242.28 share price.
Shares of AbbVie traded near $234.93 on Tuesday, with a market cap of approximately $406.38 billion.
Multiple insiders purchased shares on May 8, 2026, while analysts like Canaccord Genuity maintained buy ratings.

Get $ABBV trade alerts by text

We text you when insiders, Congress or big funds trade $ABBV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures

Piper Sandler reiterated its buy rating on AbbVie Inc. (NYSE: ABBV) on June 23, 2026, maintaining a price target of $298. This comes as the company's shares traded near $234.93 on Tuesday.

Analyst rating track record

Piper Sandler vs. the S&P 500

YTD return -14.26% hypothetical

All-time return +28.24% S&P 500 +34.82%

vs. S&P 500 -6.58% behind the index

Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On June 23, 2026, Piper Sandler reiterated its buy rating on AbbVie with a price target of $298. Canaccord Genuity also maintained a buy rating on the same day with a target of $273. Earlier, on May 15, Evercore ISI Group maintained its buy rating, setting a target of $235. Overall, AbbVie holds a consensus buy recommendation with an average target price of $253.55 based on 29 analyst opinions.

AbbVie Inc. Stock Down 14.5%

Shares of AbbVie Inc. (NYSE: ABBV) traded near $234.93 on Tuesday. The company has a market cap of about $406.38 billion and a forward P/E ratio of 14.16. Its beta is 0.309, indicating lower volatility compared to the market. The stock's 52-week range is between $181.73 and $244.81, with a 50-day moving average of $211.77 and a 200-day moving average of $220.57.

12-month forecast

$ABBV price target

AbbVie Inc. daily closes and this analyst's $298 target. Not advice.

Insider Buying and Selling at AbbVie Inc.

On May 8, 2026, several insiders, including Frederick Waddell, William H.L. Burnside, Thomas Falk, Roxanne Austin, Edward Rapp, and Brett Hart, each bought 1,118 shares of AbbVie. These transactions were not part of any pre-arranged trading plans.

About AbbVie Inc.

AbbVie Inc., headquartered in North Chicago, Illinois, is a global biopharmaceutical company engaged in the research, development, manufacture, and sale of medicines and therapies. The company offers treatments for autoimmune diseases, cancers, and neurological disorders, among others. With a workforce of 57,000 employees, AbbVie is led by CEO Robert A. Michael, CPA.

Bottom Line

Piper Sandler's reiterated buy rating on AbbVie Inc. highlights continued analyst confidence in the company's potential. With a robust market position and diverse product offerings, AbbVie remains a key player in the healthcare sector. Investors should note that analyst ratings are forward-looking opinions and may not reflect current market conditions or company performance.